Home > Retina > Emerging drug delivery approaches in retinal disease Retina Emerging drug delivery approaches in retinal disease Ophthalmology 360 <section data-block="SingleChoice"><h3>What is the current standard treatment for common retinal diseases such as AMD and DME?</h3><ul><li>Subcutaneous corticosteroid therapy</li><li>Oral anti-VEGF medications</li><li>Subretinal gene therapy</li><li>Intravitreal injections</li></ul></section><section data-block="SingleChoice"><h3>One major limitation of current intravitreal therapies is:</h3><ul><li>Lack of FDA approval</li><li>High systemic toxicity</li><li>Frequent administration due to short drug half-life</li><li>Poor response in all retinal diseases</li></ul></section><section data-block="SingleChoice"><h3>What is a key challenge in developing new retinal drug delivery systems?</h3><ul><li>Managing systemic drug interactions</li><li>Overcoming the blood-retinal barrier</li><li>Increasing IOP in all cases</li><li>FDA refusal to approve ocular drugs</li></ul></section><section data-block="SingleChoice"><h3>Future success in retinal drug delivery depends on which of the following strategies?</h3><ul><li>Minimizing collaboration to reduce bias</li><li> Limiting clinical trials to small populations</li><li>Advancing smart delivery systems and predictive models</li><li>Increasing dosing frequency for stronger effect</li></ul></section><section data-block="SingleChoice"><h3>What is the current standard treatment for common retinal diseases such as AMD and DME?</h3><ul><li>Subcutaneous corticosteroid therapy</li><li>Oral anti-VEGF medications</li><li>Subretinal gene therapy</li><li>Intravitreal injections</li></ul></section><section data-block="SingleChoice"><h3>One major limitation of current intravitreal therapies is:</h3><ul><li>Lack of FDA approval</li><li>High systemic toxicity</li><li>Frequent administration due to short drug half-life</li><li>Poor response in all retinal diseases</li></ul></section><section data-block="SingleChoice"><h3>What is a key challenge in developing new retinal drug delivery systems?</h3><ul><li>Managing systemic drug interactions</li><li>Overcoming the blood-retinal barrier</li><li>Increasing IOP in all cases</li><li>FDA refusal to approve ocular drugs</li></ul></section><section data-block="SingleChoice"><h3>Future success in retinal drug delivery depends on which of the following strategies?</h3><ul><li>Minimizing collaboration to reduce bias</li><li> Limiting clinical trials to small populations</li><li>Advancing smart delivery systems and predictive models</li><li>Increasing dosing frequency for stronger effect</li></ul></section> Share Related Content Retina Care 360 Quiz: Mental health risks linked to age-related eye disease Dry Eye Quiz: Understanding meibomian gland dysfunction and its management Dry Eye Quiz: Emerging Therapies in DED Cornea and External Disease Quiz: Refractive Surgery in Patients With Diabetes Neurotrophic Keratitis Quiz: Topical Insulin for Persistent Corneal Epithelial Defects Retinopathy of Prematurity Quiz: ROP Pharmacologic Strategies Share
